The Pharmacy Times® Multiple Sclerosis Resource Center is a comprehensive resource for clinical news and expert insights on treatments for multiple sclerosis.
November 12th 2024
Ocrelizumab (Ocrevus; Genentech) is used for the management and treatment of multiple sclerosis.
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Advances in Pharmacotherapy for Excessive Daytime Sleepiness Due to Narcolepsy
2.0 Credits / Neurology
View More
The Role of Long-Term Care and Consultant Pharmacists in the Management of Tardive Dyskinesia
1.0 Credit / Neurology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
1.5 Credits / Cardiology, Neurology, Rare Diseases
View More
The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of ...
1.0 Credit / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
1.0 Credit / Immunology, Neurology
View More
Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Ph...
2.0 Credits / Neurology, Psychiatry
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Collaborating Across the Continuum™: Identifying and Preventing Hepatic Encephalopathy in Long-Term Care Setti...
1.25 Credits / Neurology
View More
Study: Hydroxychloroquine Delays Disability for Least Treatable Form of Multiple Sclerosis
January 19th 2022The researchers projected that approximately 14 participants would experience a significant worsening of their walking function, however, only 8 participants had their walking function decline.
Read More